Sanjay K. Jain, MD

Loading...

Director, Division of Infectious Diseases
Albert B. Sabin Chair of Infectious Diseases
Professor, UC Department of Pediatrics

sanjay.jain@cchmc.org
(513) 636-7056
(513) 636-7655
Board Certified

About

Biography

I am professor and director of the Division of Infectious Diseases and the Albert B. Sabin chair of infectious diseases at Cincinnati Children’s. I also co-direct the Cincinnati Children’s Center for Molecular Imaging and Precision Medicine. My lab develops and evaluates novel molecular imaging technologies (CT, PET, SPECT and MRI) through animal and human studies to better understand disease pathogenesis, including antimicrobial pharmacokinetics at infection sites, host-directed therapies and pathogen-specific imaging diagnostics. Several imaging tracers developed in my laboratory, including radiolabeled antibiotics and pathogen-specific PET tracers for bacterial and fungal infections, have advanced to first-in-human studies.

I am actively involved in training the next generation of physicians, scientists and physician-scientists. From 2014 to 2022, I directed the ACGME-accredited Pediatric Infectious Diseases Fellowship Program at Johns Hopkins. I also served as co-director (2018–2021) and then director and principal investigator (2021–2025) of the NIH T32-AI052071 training grant supporting the program.

My research is supported by multiple NIH and other grants. I am a recipient of the NIH Director’s New Innovator Award (2009) and the NIH Director’s Transformative Research Award (2014). I am a founding member and past chair of the infectious diseases subgroup of the World Molecular Imaging Society and previously served on its board of trustees. I also serve as a reviewer for multiple scientific journals and NIH study panels.

Interests

Pediatric infectious diseases; CNS infections; tuberculosis / mycobacterial infections; international health

Services and Specialties

Infectious Diseases

Research Areas

Infectious Diseases

Publications

Addition of Clofazimine Enhances the Activity of Standard Treatment Regimen in a Mouse Model of Tuberculous Meningitis. Chen, X; Ruiz-Gonzalez, CE; Masias-Leon, Y; Singh, M; Peloquin, CA; Jain, SK. Journal of Infectious Diseases. 2026.

Beyond Rifampin: Evaluating Rifapentine and Rifabutin as Alternative Treatments for TB Meningitis. Chen, X; Ruiz-Gonzalez, CE; Masias-Leon, Y; Singh, M; Nino-Meza, OJ; Peloquin, CA; Artemov, D; Jain, SK. Journal of Infectious Diseases. 2026.

A clinical practice guideline for tuberculous meningitis. Donovan, J; Cresswell, FV; Tucker, EW; Davis, AG; Rohlwink, UK; Huynh, J; Solomons, R; Seddon, JA; Bahr, NC; Van Laarhoven, A; Rogozińska, E; Misra, UK; Figaji, A; Thwaites, GE. The Lancet Infectious Diseases. 2026; 26(2):e96-e111.

Intensified Treatment of Tuberculous Meningitis in Adults: A Systematic Review and Meta-analysis. Llamas-Lopez, A; Seddon, JA; Chow, FC; Upton, CM; Jain, SK; Alffenaar, J-W; Grint, DJ; Dooley, K; Aarnoutse, R; Cresswell, FV. Open Forum Infectious Diseases. 2025; 12(10):ofaf503.

Improved Radiosynthesis of [18F]-Labeled Oxazolidinone Antibiotics for Future Clinical Translation. Sarhan, M; Shelke, AM; Mane, K; Jadhav, R; Jeon, B; Nino-Meza, O; Chen, X; Freundlich, JS; Jain, SK; Carroll, L. ACS Infectious Diseases. 2025; 11(7):2009-2017.

18F-Fluorodeoxysorbitol PET for noninvasive detection of invasive mold infections: preclinical and first-in-human studies. Ruiz-Gonzalez, CE; Nino-Meza, OJ; Singh, M; Masias-Leon, Y; Kronenberg, A; Shambles, M; Chen, X; Tucker, EW; Lodge, MA; Carroll, LS; Cooke, KR; Kates, OS; Shoham, S; Zhang, SX; Jain, SK. Nature Communications. 2025; 16(1):6395.

Dynamic 11C-Para-Aminobenzoic Acid Positron Emission Tomography/Computed Tomography for Visualizing Pulmonary Mycobacteroides abscessus Infections. Masias-Leon, Y; Ruiz-Gonzalez, CE; Nino-Meza, OJ; Singh, M; Sarhan, MO; Chen, X; Flavahan, K; Kronenberg, A; Tucker, EW; Freundlich, JS; Lodge, MA; Carroll, LS; Parrish, N; Lechtzin, N; Jain, SK. American Journal of Respiratory and Critical Care Medicine. 2025; 211(7):1253-1263.

Proapoptotic Bcl-2 inhibitor as potential host directed therapy for pulmonary tuberculosis. Singh, M; Sarhan, MO; Damiba, NNL; Singh, AK; Villabona-Rueda, A; Nino-Meza, OJ; Chen, X; Masias-Leon, Y; Ruiz-Gonzalez, CE; Ordonez, AA; D'alessio, FR; Aboagye, EO; Carroll, LS; Jain, SK. Nature Communications. 2025; 16(1):3003.

Summary: Appropriate Use Criteria for the Use of Nuclear Medicine in Fever of Unknown Origin. Palestro, CJ; Abikhzer, G; Bar-Sever, Z; Bartel, T; Brady, R; Grady, EE; Israel, O; Jain, SK; Kandiah, S; Sathekge, MM; Shulkin, BL. Journal of Nuclear Medicine. 2024; 65(11):1786-1788.

Dynamic PET reveals compartmentalized brain and lung tissue antibiotic exposures of tuberculosis drugs. Chen, X; Arun, B; Nino-Meza, OJ; Sarhan, MO; Singh, M; Jeon, B; Mane, K; Shah, M; Tucker, EW; Carroll, LS; Freundlich, JS; Peloquin, CA; Ivaturi, VD; Jain, SK. Nature Communications. 2024; 15(1):6657.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

Loading ...